NCT05372614
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Tyrosine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: See trial for list of eligible HER2 activating mutations
Exclusions: Patients who have received Nerlynx/neratinib or Enhertu/DS-8201a previously; Patients with symptomatic, unstable, untreated brain or leptomeningeal metastases- see trial for details
https://ClinicalTrials.gov/show/NCT05372614